FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that weight-loss and diabetes drugs such as Lilly's (NYSE:LLY) tirzepatide are no longer in ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

A Lilly rep declined to comment to The Post. Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss ... tablet Rybelsus for adults with diabetes but not for weight management.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Lilly seeks to protect interests in compounded drug case FDA affirms ... loss drug Zepbound and diabetes medicine Mounjaro, which have the same active ingredient, tirzepatide.

Sales of the company's diabetes and weight loss treatments are soaring but not quite as fast as the company anticipated in ...

FDA allows compounding of tirzepatide injections until ... from supplying cheaper versions of Eli Lilly’s weight loss and diabetes drugs. In December, the FDA reviewed its earlier decision ...

It has been a year since the launch of Zepbound (tirzepatide ... Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating the drug ...